EP Global Communications Inc fka EPGL

[franck92]

Quaterly report

https://www.otcmarkets.com/financialReportViewer?symbol=EPGL&id=166669

Important Update :
As of the date of this disclosure (December 31, 2016), EPGL is structuring an upcoming relationship with a new start-up company called InWith Corporation, to begin in January 2017, for the purpose of building selected EPGL technologies.
EPGL has now received multiple USPTO patent allowances. EPGL expects to report within the next quarterly update, a decision from USPTO on any additional patent allowance(s). EPGL will inform our shareholders via public release immediately upon receiving such notice from the USPTO .
On April 12, 2016 EPGL signed an Agreement with Johnson & Johnson Vision
Care, Inc. (JNJVC) . EPGL has several patents now pending in the field of ophthalmic technologies, specifically the integration of electronics into contact lenses for vision correction and augmented vision applications. JNJVC has secured exclusive rights of first negotiation to all EPGL ophthalmic technologies and patents pending. EPGL has received three (3) USPTO patent allowances since our last updated disclosure.
EPGL and CooperVision, Inc. reached a Settlement Agreement in December 2015.
In December 2014, CooperVision, Inc. asked EPGL to grant the Exclusive Option to
license EPGL jointly developed ophthalmic technologies. EPGL refused to do so,
contending that the Development Agreement was breached and did not allow the
granting of the Option for several more months after all joint IP was fully filed.
EPGL threatened litigation over the issue. In May 2015, CooperVision, Inc.
suggested mediation and EPGL agreed to do so. As announced publicly in a
jointly approved January 2016 PR, after several months of negotiations, a
settlement was reached whereby, to avoid litigation, the parties would agree that
CooperVision, Inc. will retain rights and license to use the joint technology in their
products in exchange for cash payment and EPGL receiving assignment of the IP
and 100% ownership control and marketing rights worldwide.
EP Global Communications, Inc., is a research and development company with
focus on medical device design, ophthalmic medical device design, consumer
electronic device design and device technologies in the IoT space.
In 2014, all EPGL technologies and Intellectual property were selected and put
under Development Agreement by CooperVision, Inc., a leading medical device
manufacturer, for development and marketing. The EPGL team is now securing
Intellectual Properties and co-developing a family of advanced devices as a result.
This Development Agreement was publicly disclosed on August 29, 2014. In
addition, EPGL has entered an initial Agreement with Intel Corporation. EPGL has
also entered into Agreements with AT&T as of January 2015. EPGL and AT&T
have created joint Intellectual Properties and are now in the process of procuring
those properties.
EPGL Medical is the result of a reorganization which culminated in July 2012.
With a strong team of medical and scientific professionals, the Company is poised
to capture market share with innovative “smart medical and consumer electronic
devices” technologies including those that require advanced microelectronic
mechanical systems (MEMS). The Company philosophy is that healthcare is going
to become an increasingly challenging environment for both physicians and
patients. A coming boom in patients simultatneous to a possible shortage of
physicians will necessitate intuitive medical devices which can be used by a
broader variety of doctors. In short, new “smart medical devices” advanced
research and design intellectual properties will be needed more than ever. EPGL
Medical has the know-how to develop technologies which fit this coming new
healthcare environment and enable industry leaders to capture market share with
those advanced technologies.
EP Global Communications, Inc. dba